Meta description: A completed CTS trial evaluates electrophysiological effects of Gallium Arsenide 904 nm laser therapy combined with therapist guided median nerve mobilization after carpal tunnel release.
Publication date context: Published February 11 2026. A regulatory and clinical update reviews a completed study that tests electrophysiological effects when adjunct Gallium Arsenide GaAs 904 nm laser therapy is used with therapist supervised median nerve mobilization after carpal tunnel release. The clinical trial is listed on ClinicalTrials.gov under NCT07400562 and lists Galala University as sponsor. The article explains what changed and why it matters for regulators, clinicians, and patients. For more information see the official trial record: ClinicalTrials.gov NCT07400562.
What changed in postoperative care options after carpal tunnel release?
The update notes that a postoperative care approach now includes an adjunct treatment pathway combining a Gallium Arsenide 904 nm laser device with therapist guided median nerve neural mobilization exercises alongside standard postoperative care. The aim is to observe electrophysiological endpoints that reflect nerve function after surgical release for carpal tunnel syndrome. The study is registered on ClinicalTrials.gov with the identifier NCT07400562 and lists Galala University as sponsor. This change in the evidence base may influence clinical guidance and regulatory expectations for device use in the postoperative period.
How were the adjunct therapies studied and what was measured?
Interventions studied include the Gallium Arsenide 904 nm laser therapy delivered with a medical device and therapist supervised median nerve neural mobilization exercises. Standard postoperative care remained the baseline comparator. The study centers on electrophysiological outcomes, aiming to quantify changes in nerve function after carpal tunnel release. Details in the public record suggest a focus on measures such as nerve conduction related endpoints and measures of nerve excitability, though the full results are not provided in the available source.
Study design and endpoints
The trial record indicates a focus on electrophysiological endpoints. Clinicians and regulators will expect clear reporting of safety and performance data to support intended use of the adjuncts as a postoperative option.
What are the regulatory and safety considerations for this adjunct therapy?
The device involved is a Gallium Arsenide 904 nm laser system used as an adjunct to standard postoperative care for CTS. Such devices are regulated medical devices and must meet safety, performance, and labeling requirements under applicable medical device regulations. The sponsor is Galala University and the trial is publicly recorded on ClinicalTrials.gov as NCT07400562, which informs stakeholders about intended use and safety considerations. While the available source does not provide trial results, regulators will weigh electrophysiological outcomes, device safety data, and the risk benefit profile when evaluating future use guidelines.
Manufacturer statements or sponsor notes should be clearly identified as such when communicating regulatory position. The MDR style guidance requires precise statements of intended use and performance claims based on verifiable data.
What this means for patients and clinicians?
For patients with carpal tunnel syndrome who undergo surgical release, the availability of adjunct postoperative options could influence recovery strategies. Clinicians may consider integrating a laser based adjunct and nerve mobilization exercises when supported by regulatory clearance and institutional policy. However the current record shows only that the trial has evaluated electrophysiological effects; it does not present final clinical recommendations. Clinicians should rely on established postoperative protocols unless future results indicate a favorable risk benefit for these adjuncts.
FAQ
- 1. What is the focus of the study?
The study evaluates electrophysiological effects of adjunct Gallium Arsenide 904 nm laser therapy combined with therapist guided median nerve mobilization after carpal tunnel release.
- 2. Who funds the research?
The trial is sponsored by Galala University and listed on ClinicalTrials.gov under NCT07400562.
- 3. What data are available?
The public record provides trial design details and interventions but does not include final results in the source text.
- 4. What is the regulatory relevance?
The results may influence guidance on postoperative device use and safety assessment for adjunct therapies.
Conclusion and regulatory implications
The entry documents a completed study evaluating electrophysiological effects of adjunct Laser therapy and nerve mobilization after carpal tunnel release. While results are not provided in the source, the existence of this trial underscores ongoing regulatory interest in optimizing postoperative care with device based adjuncts. Stakeholders should monitor official trial updates and regulatory guidance to determine if future practice changes are warranted.
Disclaimer: This article is intended for professionals and is not legal advice. It reflects information from the source text and does not substitute for regulatory guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07400562?term=medical+device